Insights from Sisram Medical's Investor Day: A Vision for Wellness Growth

On May 21, 2026, Sisram Medical held its Investor Day at the prestigious Shanghai Bund Finance Center, bringing together institutional investors and brokerage analysts under the theme "Gathering Momentum for Beauty, Envisioning the Future." This event served as a platform to discuss the company's trajectory in the global medical aesthetics market, the progress of their China business, and the introduction of innovative solutions like DAXXIFY.

Sisram’s Evolution and Future Growth

Qiyu Chen, who serves as Executive Director and Co-CEO of Fosun International, commenced the discussions by shedding light on Sisram's evolution since its inception. Following Fosun's strategic investment and the company's listing in Hong Kong, Sisram has transformed its business from a distribution-focused model to a comprehensive system that integrates both distribution and direct sales. This evolution is pivotal as it reflects the company's commitment to expanding its operations globally.

The growth narrative includes not only a shift in operational dynamics but also an increase in global capabilities, fostering a robust foundation for future product development and market diversification. Looking forward, Sisram plans to maintain Energy-Based Devices (EBD) as its cornerstone while venturing into high-recurring revenue categories, particularly injectables and aesthetic consumables. The company aims to utilize its extensive distribution network across Israel, China, and North America to enhance operational efficiency and collaboration, thereby optimizing its value within the wellness sector.

A Strong Backing from Fosun

Yi Liu, the leader of Fosun Pharma, spoke about Sisram's unique positioning within Fosun’s broader industrial ecosystem. He emphasized that Sisram’s solid global presence and expertise in EBD positions it favourably to pursue a global aesthetic strategy. Liu highlighted how Synergies within Fosun Pharma’s diversified healthcare offerings provide Sisram with unique resources to accelerate its growth plans.

Chairman Lior Moshe Dayan and CEO Eyal Ben David articulated their commitment via video presentation, reaffirming the importance of aligning Sisram’s global strategies with the local market needs in China, thereby enhancing product introductions and clinical capabilities.

From EBD Leader to Comprehensive Wellness Provider

Jiahong Li, Co-CEO and CFO of Sisram, elaborated on the company's upgrade strategy and goals for transformation. As consumer preferences shift towards long-term skin health management, Sisram aims to transition from being solely an EBD leader to a comprehensive wellness solution provider. This involves integrating EBD with pre-treatment diagnostics, clinical procedures, and ongoing skin care management.

Utilizing advanced technologies, including Alma IQ and Universkin by Alma, Sisram aims to connect all phases of aesthetic treatment—from evaluation to long-term care—creating a holistic service chain that maximizes synergy across its business units. The company's proactive approach to exploring strategic partnerships aligns with its ambition to elevate consumer experiences and strengthen its portfolio.

Strategic Localization in China

China remains a pivotal market for Sisram, and Vice President Qianli Fang detailed their adaptation strategies, which focus on localizing product offerings based on over two decades of operational experience. As Sophistication in China's medical aesthetics market increases, Sisram is committed to interlinking its EBD and injectables businesses while enhancing customer service experiences and clinical training. This shift towards a platform-centric model aims to drive more robust customer relationships and streamline service offerings.

The commercialization of DAXXIFY, featuring proprietary Peptide Exchange Technology (PXT), is central to this strategy. By highlighting DAXXIFY's long-lasting efficacy and pure formulation, Sisram seeks to meet the growing demand within the high-end market for injectables.

Industry Insights and the Road Ahead

Haiyan Cui from Tongji University shared insights about the shifting dynamics within the medical aesthetics industry, underscoring a transition towards minimally invasive treatments and AI advancements, both of which reflect Sisram’s business focus.

As Sisram continues to integrate EBD, injectables, and AI diagnostic technologies, it is poised for sustained growth in the global aesthetic sector. The Investor Day concluded with a clear validation of Sisram’s strategic objectives, ensuring they remain at the forefront of the wellness industry developments in both domestic and global markets.

With a commitment to innovation and localization, Sisram is set on a path to empower the medical aesthetics landscape by consistently enhancing its operational frameworks and product offerings, ensuring high-quality growth in the future.